Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors

Croce, 2009, Evolution of the Wnt pathways, Wnt Signaling, 3

Willert, 2003, Wnt proteins are lipid-modified and can act as stem cell growth factors, Nature, 423, 448, 10.1038/nature01611

MacDonald, 2009, Wnt/β-catenin signaling: components, mechanisms, and diseases, Dev Cell, 17, 9, 10.1016/j.devcel.2009.06.016

Wu, 2010, GSK3: a multifaceted kinase in Wnt signaling, Trends Biochem Sci, 35, 161, 10.1016/j.tibs.2009.10.002

Bilić, 2007, Wnt induces LRP6 signalosomes and promotes disheveled-dependent LRP6 phosphorylation, Science, 316, 1619, 10.1126/science.1137065

Gordon, 2006, Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors, J Biol Chem, 281, 22429, 10.1074/jbc.R600015200

Spiegelman, 2000, Wnt/β-catenin signaling induces the expression and activity of βTrCP ubiquitin ligase receptor, Mol Cell, 5, 877, 10.1016/S1097-2765(00)80327-5

Kohn, 2005, Wnt and calcium signaling: β-catenin-independent pathways, Cell Calcium, 38, 439, 10.1016/j.ceca.2005.06.022

Topol, 2003, Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent β-catenin degradation, J Cell Biol, 162, 899, 10.1083/jcb.200303158

Okamoto, 2014, Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis, Sci Rep, 27, 4493, 10.1038/srep04493

Holmen, 2002, A novel set of Wnt-Frizzled fusion proteins identifies receptor components that activate β-catenin-dependent signaling, J Biol Chem, 277, 34727, 10.1074/jbc.M204989200

Jiang, 2015, Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases, Mol Cell, 58, 522, 10.1016/j.molcel.2015.03.015

MacDonald, 2012, Frizzled and LRP5/6 Receptors for Wnt/β-Catenin Signaling, Cold Spring Harbor Perspect Biol, 4, a007880, 10.1101/cshperspect.a007880

Jernigan, 2010, Gβγ activates GSK3 to promote LRP6-mediated β-catenin transcriptional activity, Sci Signal, 3, Ra37, 10.1126/scisignal.2000647

Kim, 2013, Wnt stabilization of β-catenin reveals principles for morphogen receptor-scaffold assemblies, Science, 340, 867, 10.1126/science.1232389

Hart, 1998, Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β, Curr Biol, 8, 573, 10.1016/S0960-9822(98)70226-X

Zeng, 2008, Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions, Development, 135, 367, 10.1242/dev.013540

Schneider, 2012, Differential role of Axin RGS domain function in Wnt signaling during anteroposterior patterning and maternal axis formation, PLoS ONE, 7, e44096, 10.1371/journal.pone.0044096

Bienz, 2000, Linking colorectal cancer to Wnt signaling, Cell, 103, 311, 10.1016/S0092-8674(00)00122-7

Aoki, 2007, Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene, J Cell Sci, 120, 3327, 10.1242/jcs.03485

Loregger, 2015, The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated b-catenin by sequestering TCF4 to the nuclear membrane, Sci Signal, 8, 393, 10.1126/scisignal.aac6757

Zebisch, 2013, Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin, Nature Commun, 14, 4

Collu, 2014, Wnt-Notch signalling crosstalk in development and disease, Cell Mol Life Sci, 71, 3553, 10.1007/s00018-014-1644-x

Borggrefe, 2016, The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. Biochimica et Biophysica Acta (BBA)-Molecular, Cell Res, 1863, 303

Ann, 2012, Wnt5a controls Notch1 signaling through CaMKII-mediated degradation of the SMRT corepressor protein, J Biol Chem, 287, 36814, 10.1074/jbc.M112.356048

Song, 2015, Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy, Cancer Biol Ther, 16, 1, 10.4161/15384047.2014.972215

Wang, 2006, Evidence for the direct involvement of beta TrCP in Gli3 protein processing, Proc Natl Acad Sci U S A, 103, 33, 10.1073/pnas.0509927103

Meng, 2001, Suppressor of fused negatively regulates beta-catenin signaling, J Biol Chem, 276, 40113, 10.1074/jbc.M105317200

Riffell, 2012, Tankyrase-targeted therapeutics: expanding opportunities in the PARP family, Nat Rev Drug Discovery, 11, 923, 10.1038/nrd3868

Tian, 2013, XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway, J Exp Clin Cancer Res, 32, 1, 10.1186/1756-9966-32-100

Ma, 2015, Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells, Oncotarget, 6, 25390, 10.18632/oncotarget.4455

Wessel Stratford, 2014, The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines, Cancer Med, 3, 36, 10.1002/cam4.170

Mo, 2013, Inhibition of the Wnt palmitoyl transferase porcupine suppresses cell growth and downregulates the Wnt/β-catenin pathway in gastric cancer, Oncol Lett, 5, 1719, 10.3892/ol.2013.1256

Fujii, 2007, An Antagonist of Dishevelled Protein-Protein Interaction Suppresses β-Catenin–Dependent Tumor Cell Growth, Can Res, 67, 573, 10.1158/0008-5472.CAN-06-2726

Shan, 2012, Synthesis of potent dishevelled PDZ domain inhibitors guided by virtual screening and NMR studies, Chem Biol Drug Des, 79, 376, 10.1111/j.1747-0285.2011.01295.x

Gandhirajan, 2010, Small molecule inhibitors of Wnt/β-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo, Neoplasia, 12, 10.1593/neo.91972

Arensman, 2014, The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth, Mol Cancer Ther, 13, 2303, 10.1158/1535-7163.MCT-13-1005

Hallett, 2012, Small molecule antagonists of the Wnt/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer, PLoS ONE, 7, e33976, 10.1371/journal.pone.0033976

Masuda, 2015, Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer, Pharmacol Ther, 31, 1, 10.1016/j.pharmthera.2015.10.009

Liu, 2013, Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974, Proc Natl Acad Sci, 110, 20224, 10.1073/pnas.1314239110

Smith, 2013, First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors, J Clin Oncol, 31

Le, 2015, Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28, Pharmacol Ther, 28, 1, 10.1016/j.pharmthera.2014.08.005

Fischer, 2017, WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death, Sci Adv, 3, e1700090, 10.1126/sciadv.1700090

Canesin, 2017, Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model, PLoS ONE, 12, e0184418, 10.1371/journal.pone.0184418

Fukukawa, 2008, Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10, Cancer Sci, 99, 432, 10.1111/j.1349-7006.2007.00701.x

Cortes, 2015, Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), vol. 33, No. 15_suppl, 7044

Lenz, 2014, Safely targeting cancer stem cells via selective catenin coactivator antagonism, Cancer Sci, 105, 1087, 10.1111/cas.12471

Pozzi, 2013, In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma, Bone, 53, 487, 10.1016/j.bone.2013.01.012

Ko AH, Chiorean EG, Kwak EL, Lenz HJ, Nadler PI, Wood DL et al. Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. 2016.

Arend, 2014, Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer, Gynecol Oncol, 134, 112, 10.1016/j.ygyno.2014.04.005

Tai, 2014, The inhibition of Wnt/β-catenin signaling pathway in human colon cancer cells by sulindac, Tumori, 100, 97

Li, 2014, Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis, PLoS ONE, 9, e101969, 10.1371/journal.pone.0101969

Krop, 2012, Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors, J Clin Oncol, 30, 2307, 10.1200/JCO.2011.39.1540

Schott, 2013, Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors, Clin Cancer Res, 19, 1512, 10.1158/1078-0432.CCR-11-3326

Yao, 2010, Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway, Med Oncol, 27, 1017, 10.1007/s12032-009-9326-5

Tolcher, 2012, Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors, J Clin Oncol, 30, 2348, 10.1200/JCO.2011.36.8282

De Jesus-Acosta, 2014, A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma, Invest New Drugs, 32, 739, 10.1007/s10637-014-0083-8

Papayannidis, 2015, A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, Blood Cancer J, 5, e350, 10.1038/bcj.2015.80

Zweidler-McKay, 2014, The safety and activity of BMS-906024, a gamma secretase inhibitor (GSI) with anti-notch activity, in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL): initial results of a phase 1 trial, Blood, 124, 968, 10.1182/blood.V124.21.968.968

Jenkins, 2012, MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo, Mol Cancer Ther, 10.1158/1535-7163.MCT-11-1027

Patnaik, 2014, Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors, Eur J Cancer, 1, 7, 10.1016/S0959-8049(14)70128-5

Catenacci, 2015, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, J Clin Oncol, 33, 4284, 10.1200/JCO.2015.62.8719

Steg, 2012, Smoothened antagonists reverse taxane resistance in ovarian cancer, Mol Cancer Ther, 11, 1587, 10.1158/1535-7163.MCT-11-1058

Aberger, 2017, Acute myeloid leukemia–strategies and challenges for targeting oncogenic Hedgehog/GLI signaling, Cell Commun Signal, 15, 8, 10.1186/s12964-017-0163-4

Campbell VT, Nadesan PP, Wang Y, Whetstone H, McGovern K, Read M et al. Abstract LB-380: Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened inhibitor IPI-926. 2011.

Vermeulen, 2010, Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, Nat Cell Biol, 12, 468, 10.1038/ncb2048

Giannakis, 2014, RNF43 is frequently mutated in colorectal and endometrial cancers, Nat Genet, 46, 1264, 10.1038/ng.3127

Seshagiri, 2012, Recurrent R-spondin fusions in colon cancer, Nature, 488, 660, 10.1038/nature11282

Khramtsov, 2010, Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome, Am J Pathol, 176, 2911, 10.2353/ajpath.2010.091125

Schade, 2013, Β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression, Can Res, 73, 4474, 10.1158/0008-5472.CAN-12-3925

Teng, 2010, Wnt/β-catenin signaling regulates cancer stem cells in lung cancer A549 cells, Biochem Biophys Res Commun, 392, 373, 10.1016/j.bbrc.2010.01.028

Staal, 2008, The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis, Eur J Immunol, 38, 1788, 10.1002/eji.200738118

Peterson, 2009, Wnt-Pathway Directed Compound Targets Blast Crisis and Chronic Phase CML Leukemia Stem Progenitors, Blood, 114, 2168, 10.1182/blood.V114.22.2168.2168

Nagaraj, 2015, Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance, Oncotarget, 6, 23720, 10.18632/oncotarget.4690

Huss, 2013, Β-Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis, Histopathology, 62, 294, 10.1111/j.1365-2559.2012.04355.x

Wang, 2013, The development of highly potent inhibitors for porcupine, J Med Chem, 56, 2700, 10.1021/jm400159c

Giefing, 2016, Takes RP. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data, Eur J Cancer, 31, 147, 10.1016/j.ejca.2015.10.070

Koo, 2015, Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43; Znrf3-mutant neoplasia, Proc Natl Acad Sci, 112, 7548, 10.1073/pnas.1508113112

Teneggi, 2016, 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours, Ann Oncol, 27, 10.1093/annonc/mdw579.004

He, 2004, A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells, Neoplasia, 6, 7, 10.1016/S1476-5586(04)80048-4

Mikami, 2005, Efficacy of Wnt-1 monoclonal antibody in sarcoma cells, BMC Cancer, 5, 53, 10.1186/1471-2407-5-53

Jimeno A, Gordon MS, Chugh R, Messersmith WA, Mendelson DS, Dupont J et al. A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors. 2014.

Yeung, 2014, Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models, 5

Weekes, 2016, Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC), Ann Oncol, 27, 367PD

Arqués, 2016, Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer, Clin Cancer Res, 22, 644, 10.1158/1078-0432.CCR-14-3081

Zhong, 2016, Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index< 1, Toxicol Pathol, 44, 267, 10.1177/0192623315621192

Grandy, 2009, Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled, J Biol Chem, 284, 16256, 10.1074/jbc.M109.009647

Lepourcelet, 2004, Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex, Cancer Cell, 5, 91, 10.1016/S1535-6108(03)00334-9

Säfholm, 2008, The Wnt-5a–derived hexapeptide foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility, Clin Cancer Res, 14, 6556, 10.1158/1078-0432.CCR-08-0711

Kurayoshi, 2006, Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion, Can Res, 66, 10439, 10.1158/0008-5472.CAN-06-2359

Soerensen PG, Andersson T, Buhl U, Moelvadgaard T, Jensen PB, Brunner N, et al. Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer. 2014.

Barat, 2017, Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44+ Gastric Cancer Stem Cells, Stem Cells Translat Med, 6, 819, 10.1002/sctm.16-0335

Piha-Paul, 2015, Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours, Eur J Cancer, 51, 1865, 10.1016/j.ejca.2015.06.115

Olsauskas-Kuprys, 2013, Gamma secretase inhibitors of Notch signaling, Onco Targets Ther, 1, 943

Gounder, 2015, Notch inhibition in desmoids: “Sure it works in practice, but does it work in theory?”, Cancer, 121, 3933, 10.1002/cncr.29562

Infante, 2015, Targeting GLI factors to inhibit the Hedgehog pathway, Trends Pharmacol Sci, 36, 547, 10.1016/j.tips.2015.05.006

Zhou, 2014, Combination of tyrosine kinase inhibitor with β-Catenin/CBP modulator C82 reverses TKI resistance, eradicates quiescent CML stem/progenitors cells, and overcomes MSC-associated microenvironmental protection, Blood, 124, 401, 10.1182/blood.V124.21.401.401

White, 2012, Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers, Gastroenterology, 142, 219, 10.1053/j.gastro.2011.12.001

Hung HT, Ong R, Puehler F, Scholz A, Politz O, Zopf D et al. Sorafenib/Refametinib potently inhibits Wnt/β-catenin in vitro and patient-derived xenograft models of human hepatocellular carcinoma. 2016.

Messersmith, 2015, A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014, Clin Cancer Res, 21, 60, 10.1158/1078-0432.CCR-14-0607